Table 4.

Diagnostic testing during the 5 years prior to ATTRv amyloidosis diagnosis

	Newly diagnosed ATTRv Amyloidosis Patients N = 141	Matched controlsa N = 423	p value	Newly diagnosed ATTRv Amyloidosis Patients N = 141	Matched controlsa N = 423	p value	Newly diagnosed ATTRv Amyloidosis Patients N = 141	Matched controlsa N = 423	p value
	Pyrophosphate imaging (PYP)			Cardiac magnetic resonance imaging (MRI)			Echocardiogram
N (%)	3 (2.1)	0 (0.0)	0.003	10 (7.1)	1 (0.2)	< 0.001	80 (56.7)	114 (27.0)	< 0.001
First evidence occurred	138 (97.9)	423 (100.0)	0.003	131 (92.9)	422 (99.8)	< 0.001	61 (43.3)	309 (73.0)	< 0.001
No evidence
Pre Y1	3 (2.1)	0 (0)		6 (4.3)	1 (0.2)		12 (8.5)	19 (4.5)
Pre Y2	0 (0)	0 (0)		1 (0.7)	0 (0)		11 (7.8)	14 (3.3)
Pre Y3	0 (0)	0 (0)		1 (0.7)	0 (0)		11 (7.8)	19 (4.5)
Pre Y4	0 (0)	0 (0)		2 (1.4)	0 (0)		19 (13.5)	21 (5.0)
Pre Y5	0 (0)	0 (0)		0 (0)	0 (0)		27 (19.1)	41 (9.7)

	Blood/urine testing		p value	Tissue biopsy or genetic testingb		p value
N (%)	49 (34.8)	40 (9.5)	< 0.001	49 (34.8)	88 (20.8)	< 0.001
First evidence occurred			< 0.001			0.003
No evidence	92 (65.2)	383 (90.5)		92 (65.2)	335 (79.2)
Pre Y1	14 (9.9)	13 (3.1)		11 (7.8)	14 (3.3)
Pre Y2	7 (5.0)	6 (1.4)		7 (5.0)	12 (2.8)
Pre Y3	10 (7.1)	7 (1.7)		13 (9.2)	14 (3.3)
Pre Y4	10 (7.1)	7 (1.7)		10 (7.1)	21 (5.0)
Pre Y5	8 (5.7)	7 (1.7)		8 (5.7)	27 (6.4)

ATTRv Hereditary transthyretin

^aMatched with age, gender, and region

^bTissue biopsy tests limited to peripheral, cardiac, salivary, rectal, fat pad areas of the body and nerves, and genetic tests include those used to analyze nucleic acid for abnormalities that may be indicative of a variety of disorders